Tryptophan/Kynurenine Trap

NoteOpen Question: Neurotoxic Kynurenine Dominance

Tryptophan metabolism sits at a critical junction: it can be converted to serotonin (mood, sleep, gut function) or shunted into the kynurenine pathway (immune regulation, NAD+ synthesis). Immune activation diverts tryptophan toward kynurenine via IDO and TDO enzymes.

The kynurenine pathway then branches: one arm produces neuroprotective kynurenic acid (KYNA), the other produces neurotoxic quinolinic acid (QUIN). What if ME/CFS involves persistent shunting toward kynurenine combined with preferential flux through the quinolinic acid branch?

This single metabolic disturbance could simultaneously explain:

  • Depleted serotonin (mood disturbance, sleep dysfunction, gut dysmotility)
  • Neuroinflammation and excitotoxicity (cognitive dysfunction, sensory sensitivities)
  • Disrupted NAD+ synthesis (energy metabolism impairment)
  • Immune dysregulation (kynurenines are immunomodulatory)

The NIH deep phenotyping study found significant tryptophan pathway abnormalities in ME/CFS patients, lending some empirical support to this direction.

1 Tryptophan Metabolism Overview

Tryptophan is an essential amino acid with two major metabolic fates:

Serotonin Pathway (\(\sim\) 5% of tryptophan).

Tryptophan \(\rightarrow^{\text{TPH}}\) 5-HTP \(\rightarrow^{\text{AADC}}\) Serotonin β†’ Melatonin :::

This pathway produces neurotransmitters essential for mood, sleep, cognition, and gut function.

Kynurenine Pathway (\(\sim\) 95% of tryptophan).

\[ \text{Tryptophan} \rightarrow^{\text{IDO/TDO}} \text{Kynurenine} \rightarrow cases( \text{Kynurenic acid (KYNA)} \text{3-HK} \rightarrow \text{Quinolinic acid (QUIN)} \rightarrow \text{NAD+} ) \]

:::

The branch point is critical:

  • KYNA: NMDA receptor antagonist, neuroprotective, anti-inflammatory
  • QUIN: NMDA receptor agonist, neurotoxic, pro-inflammatory, generates ROS

2 The Trap Mechanism

Immune activation (IFN-\(\gamma\), IL-6) strongly induces IDO, shunting tryptophan toward kynurenine. This is normally adaptiveβ€”it depletes tryptophan that pathogens need and generates immunomodulatory metabolites.

The β€œtrap” occurs when:

  • IDO activation persists beyond the acute phase
  • Kynurenine preferentially flows toward QUIN rather than KYNA
  • QUIN causes neuroinflammation and oxidative stress
  • Neuroinflammation maintains cytokine production
  • Cytokines perpetuate IDO activation

This creates a self-sustaining loop where the pathway that should eventually suppress inflammation instead maintains it.

3 Consequences of the Trap

Serotonin Depletion. With tryptophan diverted to kynurenine, less is available for serotonin synthesis. This contributes to:

  • Depressed mood (though different from primary depression)
  • Sleep disturbances (melatonin is downstream of serotonin)
  • Gut dysmotility (gut contains 90% of body’s serotonin)
  • Cognitive impairment (serotonin modulates cognition)

Quinolinic Acid Neurotoxicity. QUIN accumulation causes:

  • NMDA receptor overactivation and excitotoxicity
  • Oxidative stress and lipid peroxidation
  • Astrocyte and microglial activation
  • Blood-brain barrier disruption
  • Direct neuronal damage

NAD+ Disruption. While QUIN eventually becomes NAD+, the pathway may be inefficient or the intermediate toxicity may outweigh benefits. Additionally, NAD+ consumption by inflammation-activated PARPs may exceed synthesis.

4 Testable Predictions

  • ME/CFS patients should show elevated QUIN:KYNA ratios in plasma and/or CSF
  • IDO expression/activity should be chronically elevated
  • Serotonin and melatonin levels should be reduced
  • Interventions blocking IDO or shifting the pathway toward KYNA might help
  • NAD+ precursor supplementation might be beneficial
  • The severity of kynurenine imbalance should correlate with specific symptoms